Chronic Myeloid Leukemia (CML) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033 thelansis.com

Chronic myeloid leukemia (CML), a type of myeloproliferative disorder, represents a significant proportion of leukemia cases globally. Its hallmark is the presence of the Philadelphia chromosome, arising from a specific translocation between chromosomes 9 and 22 (t(9;22)(q34;q11.2)), which generates an aberrant tyrosine kinase due to the BCR/ABL gene fusion. While CML isn’t hereditary, the exact factors predisposing individuals to this condition remain unclear. CML typically progresses through three phases: chronic (CML-CP), accelerated (CML-AP), and blast (CML-BP). Diagnosis often occurs during the chronic phase, which might be asymptomatic or manifest with symptoms like fatigue, anemia, weight loss, night sweats, or an enlarged spleen. Treatment strategies for chronic myeloid leukemia vary based on disease stage. In the asymptomatic chronic phase, initial therapy usually involves tyrosine kinase inhibitors (such as imatinib, nilotinib, dasatinib, bosutinib, and ponatinib), demonstrating high efficacy, although not curative. These inhibitors may also be employed in the accelerated or blast phases. Allogeneic hematopoietic stem cell transplantation is typically reserved for patients with advanced CML or those resistant to tyrosine kinase inhibitors. The advent of tyrosine kinase inhibitors has markedly improved survival rates for chronic phase CML, exceeding 90% at the 5-year mark post-diagnosis. Before their availability, despite treatment, mortality rates were notably higher, with 5 to 10% succumbing within 2 years of diagnosis and an additional 10 to 15% annually after that, resulting in a median survival of 4 to 7 years. Most deaths, around 90%, occurred following progression to blast or accelerated phases, with a median survival of approximately 3 to 6 months in blast crisis unless remission was achieved.
• The annual incidence of CML ranges from 0.4 to 1.75 cases per 100,000 individuals globally.

Thelansis’s “Chronic Myeloid Leukemia (CML) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Chronic Myeloid Leukemia (CML) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Chronic Myeloid Leukemia (CML) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Chronic Myeloid Leukemia (CML) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Chronic Myeloid Leukemia (CML) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Tags: Chronic Myeloid Leukemia (CML), Chronic Myeloid Leukemia (CML) market outlook, Chronic Myeloid Leukemia (CML) competitive landscape, Chronic Myeloid Leukemia (CML) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)